Mentoring and Research in Placebo Studies, Asian Medicine and CAM

描述（申请人提供）：目标：该提案要求获得职业中期K24奖，为Ted Kaptchuk博士提供受保护的时间，以1）稳定和扩大他对初级研究者的指导，主要是安慰剂研究领域，其次是亚洲医学和CAM领域，以及2）提高他在基础科学和社会科学以及生物伦理学方面的研究技能，以提高他领导安慰剂研究创新项目的能力。背景：安慰剂，医疗仪式和医患关系对健康结果的影响的研究往往被边缘化。这笔赠款旨在加强Pi的议程，即使用科学方法来调查所有治疗的基础医学组成部分。重要的是，该补助金还旨在开发多学科方法，将基础，临床和社会科学结合起来，以促进临床翻译，并抵消仅从单一学科带来的方法或理论所带来的偏见或限制。资质要求：该候选人具有独特的背景和丰富的经验，曾担任多个R 01和R21的PI或co-Pi、P01和U19的项目负责人以及其他R 01、R21和U 01的联合研究员。他已经在指导K 01，K23，R21和U19受助人和培养初级研究人员方面取得了成功的记录。工作环境：哈佛大学丰富的研究环境以及戈德曼、古德、罗森、克莱曼、波图拉基斯、伯林、哈灵顿、菲利普斯和戴维斯等杰出的哈佛教授的积极投入，为候选人的议程创造了一个独特的框架。导师计划：作为哈佛医学院（HMS）跨部门安慰剂网络和HMS亚洲医学项目的主席，PI创造了独特的结构，吸引了来自哈佛许多研究机构和主要教学医院的初级研究人员和资深教师。此外，作为一个完善的NCCAM资助的T32 CAM奖学金计划在HMS的副主任，PI是所有CAM领域的初级研究人员的资源。培训内容：在生物伦理学和基础生物学和社会科学方面的实践培训和正式教学学习将加强候选人领导多学科团队的能力。调研：候选人建议扩展一项大型成功的RCT（n=287），该RCT评价安慰剂效应是否可以以“剂量依赖性”方式给药，以探索几种可检验的机制假设，即安慰剂效应是否可归因于生理学、心理学、遗传学、社会学和人类学变量。重要性：该K24将支持下一代研究者，并有助于为主要研究者在安慰剂研究中的未来多学科P01和R 01应用提供科学和制度框架。

DESCRIPTION (provided by applicant): Goal: This proposal requests a Midcareer K24 award to provide Dr. Ted Kaptchuk with protected time to 1) stabilize and expand his mentoring of junior investigators primarily in the domain of placebo studies and secondarily, in Asian medicine and CAM, and 2) increase his research skills in the basic and social sciences and in bioethics to enhance his capacity to lead innovative projects in placebo studies. Background: The study of the impact of placebo, medical ritual and the patient-practitioner relationship on health outcomes is often marginalized. This grant seeks to strengthen the Pi's agenda of using scientific methodologies to investigate these components of medicine that underlie all healing. Importantly, this grant also seeks to develop multi-disciplinary approaches that incorporate basic, clinical and social sciences to foster clinical translation and to counteract bias or limitations imposed by methods or theories brought to the problem from only a single discipline. Qualifications: The candidate has a unique background and extensive experience as PI or co-Pi on multiple R01s and R21s, as project leader for a P01 and a U19, and co-investigator on other R01s, R21s and U01s. He already has a successful track record in mentoring K01, K23, R21 and U19 grantees and nurturing junior researchers. Environment: Harvard University's rich research environment and the active commitment of such distinguished Harvard professors as Drs. Goldman, Good, Rosen, Kleinman, Pothoulakis, Buring, Harrington, Phillips and Davis create a unique framework for the candidate's agenda. Mentoring Program: As chair of Harvard Medical School's (HMS) cross-departmental Placebo Network and HMS' Program in Asian Medicine, the PI has created unique structures that attract both junior investigators and established senior faculty from Harvard's many research institutions and major teaching hospitals. Also, as associate director of a well-established NCCAM-funded T32 CAM fellowship program at HMS, the PI is a resource for junior researchers across all CAM domains. Training: Hands-on training and formal didactic learning in bioethics and the basic biological and social sciences will strengthen the candidate's ability to lead multi-disciplinary teams. Research: The candidate proposes to extend a large successful RCT (n=287), that evaluates whether placebo effects can be administered in a "dose dependent" manner to explore several testable mechanistic hypotheses on whether placebo response can be attributed to physiological, psychological, genetic, sociological and anthropological variables. Significance: This K24 will support a future generation of investigators and help provide the scientific and institutional framework for future multi-disciplinary P01 and R01 applications in placebo studies by the Principle Investigator.